2.75 semaglutide U.S. FDA | The FDA has approved a new higher dose (7.2 mg) of Wegovy ( semaglutide) injection, Wegovy HD, for weight loss and long-term weight Semaglutide 7.2mg achieved 20.7% weight

Based on these Phase 2 results, Eli Lilly initiated a comprehensive Phase 3 program spanning multiple trials in both obesity (ATTAIN series) and type 2 diabetes (ACHIEVE series)

Retatrutide targets three gut hormone receptors, tirzepatide targets two

& Hubbard, E

American Diabetes Association, 2020)

Sleep disruption, hot flashes, fatigue and brain fog are increasingly met with highly specific recommendations: optimize your hormones, consider HRT or explore peptides

Initiation of GLP-1 therapy follows a gradual dose-escalation protocol designed to minimize gastrointestinal adverse effects while achieving therapeutic benefit